Outcomes of extensive-stage small cell lung cancer treatment in a real-world clinical setting: a single-center experience

Kresimir Tomic; Emir Begagic; Ema Voloder; Maja Pezer Naletilic; Gordana Beric Jozic; Sanda Cale; Marija Peric; Dragana Miletic; Lejla Abaza; Dragana Karan Krizanac; Kristina Galic; Inga Marijanovic; Edo Vrdoljak; Semir Vranic

doi:10.5114/wo.2025.153755

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2025
vol. 29

Send email

Copy url:

abstract:

Original paper

Outcomes of extensive-stage small cell lung cancer treatment in a real-world clinical setting: a single-center experience

Kresimir Tomic

¹

,

Emir Begagic

²

,

Ema Voloder

¹

,

Maja Pezer Naletilic

¹

,

Gordana Beric Jozic

¹

,

Sanda Cale

¹

,

Marija Peric

¹

,

Dragana Miletic

¹

,

Lejla Abaza

³

,

Dragana Karan Krizanac

¹

,

Kristina Galic

¹

,

Inga Marijanovic

¹

,

Edo Vrdoljak

⁴

,

Semir Vranic

⁵

University Clinical Hospital Mostar, Bosnia and Herzegovina
Cantonal Hospital Zenica, Bosnia and Herzegovina
Cantonal Hospital Dr. Safet Mujic, Bosnia and Herzegovina
University Hospital Split, Croatia
College of Medicine, Qatar University, Qatar

Contemp Oncol (Pozn) 2025; 29 (3): 271–280

DOI: https://doi.org/10.5114/wo.2025.153755

Online publish date: 2025/08/25

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Tomic K, Begagic E, Voloder E, et al. Outcomes of extensive-stage small cell lung cancer treatment in a real-world clinical setting: a single-center experience. Contemporary Oncology/Współczesna Onkologia. 2025;29(3):271-280. doi:10.5114/wo.2025.153755.

APA

Tomic, K., Begagic, E., Voloder, E., Naletilic, M., Jozic, G.,  & Cale, S. et al. (2025). Outcomes of extensive-stage small cell lung cancer treatment in a real-world clinical setting: a single-center experience. Contemporary Oncology/Współczesna Onkologia, 29(3), 271-280. https://doi.org/10.5114/wo.2025.153755

Chicago

Tomic, Kresimir, Emir Begagic, Ema Voloder, Maja Pezer Naletilic, Gordana Beric Jozic, Sanda Cale,  and Marija Peric et al. 2025. "Outcomes of extensive-stage small cell lung cancer treatment in a real-world clinical setting: a single-center experience". Contemporary Oncology/Współczesna Onkologia 29 (3): 271-280. doi:10.5114/wo.2025.153755.

Harvard

Tomic, K., Begagic, E., Voloder, E., Naletilic, M., Jozic, G., Cale, S., Peric, M., Miletic, D., Abaza, L., Krizanac, D., Galic, K., Marijanovic, I., Vrdoljak, E.,  and Vranic, S. (2025). Outcomes of extensive-stage small cell lung cancer treatment in a real-world clinical setting: a single-center experience. Contemporary Oncology/Współczesna Onkologia, 29(3), pp.271-280. https://doi.org/10.5114/wo.2025.153755

MLA

Tomic, Kresimir et al. "Outcomes of extensive-stage small cell lung cancer treatment in a real-world clinical setting: a single-center experience." Contemporary Oncology/Współczesna Onkologia, vol. 29, no. 3, 2025, pp. 271-280. doi:10.5114/wo.2025.153755.

Vancouver

Tomic K, Begagic E, Voloder E, Naletilic M, Jozic G, Cale S et al. Outcomes of extensive-stage small cell lung cancer treatment in a real-world clinical setting: a single-center experience. Contemporary Oncology/Współczesna Onkologia. 2025;29(3):271-280. doi:10.5114/wo.2025.153755.

PlumX metrics:

Introduction:
Small cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer that accounts for approximately 15% of all lung cancers. Despite advancements in treatment, real-world clinical practice in developing countries often reveals less favorable outcomes than those observed in randomized clinical trials.

Material and methods:
A retrospective analysis was conducted on all patients with extensive-stage SCLC (ES-SCLC) diagnosed or treated at a single center in Bosnia and Herzegovina. Medical and electronic health records were reviewed to collect data on patients diagnosed with ES-SCLC between 2013 and 2023. The analysis included patient demographics, clinical characteristics, treatment outcomes, and adverse events.

Results:
Ninety-four patients with ES-SCLC were included in the study. Of these, 89.4% were prescribed first-line treatment, and 63.8% received first- line chemotherapy based on cisplatin and etoposide. The median progression- free survival in patients treated with first-line ES-SCLC was five months, with a response rate of 57.5%. The median overall survival of patients treated with first-line chemotherapy in our study was seven months. The most common side effect was hematologic toxicity.

Conclusions:
Our results showed that the outcomes of patients with ES-SCLC in real clinical practice are poor. Further studies of real-world treatment outcomes are essential to validate the findings from randomized controlled trials. Ongoing research is needed to explore strategies for improving outcomes and addressing the unmet needs of patients with ES-SCLC.

keywords:

Outcomes of extensive-stage small cell lung cancer treatment in a real-world clinical setting: a single-center experience

Kresimir Tomic 1 , Emir Begagic 2 , Ema Voloder 1 , Maja Pezer Naletilic 1 , Gordana Beric Jozic 1 , Sanda Cale 1 , Marija Peric 1 , Dragana Miletic 1 , Lejla Abaza 3 , Dragana Karan Krizanac 1 , Kristina Galic 1 , Inga Marijanovic 1 , Edo Vrdoljak 4 , Semir Vranic 5

small cell lung cancer, extensive stage, chemotherapy, first line, real-world data